$ONCBeOne Medicines Ltd.

📅 Upcoming

🕒 Recent(90d)

News

• Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
  Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.
  fiercebiotech · 6d ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 16d ago
• BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
  The addition of small molecule capacity at BeOne Medicines’ Hopewell site will support the company’s hematology efforts and bring total investment in the campus to more than $1 billion.
  biospace · 19d ago
• Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
  Lupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit targets purs…
  fiercebiotech · 22d ago
• Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
  The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
  biopharma_dive · 1mo ago
• BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study
  BeOne Medicines said its BTK inhibitor Brukinsa cut the risk of disease progression or death by 43% compared to chemoimmunotherapy when used as a first option for mantle cell lymphoma patients. The…
  endpoints · 1mo ago
• Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers
  Hundreds of executives and investors are pushing for Rick Pazdur to be the next FDA commissioner. Elsewhere, Takeda detailed its latest restructuring and Alumis is discarding a once-highly touted i…
  biopharma_dive · 2mo ago
• BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta
  BeOne Medicines has clinched an accelerated approval for its drug sonrotoclax in mantle cell lymphoma (MCL), marking the start of its bid to challenge AbbVie and Roche's Venclexta across a range of…
  endpoints · 2mo ago
• BeOne culls five cancer programs and an autoimmune Phase 2
  BeOne Medicines has greatly expanded its pipeline over the years, bringing 18 new molecular entities to the fore across 2024 and 2025. But that also means the drugmaker will likely cull more experi…
  endpoints · 3mo ago
• BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
  The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and…
  endpoints · 3mo ago